Apellis and growth products moved Biogen's 2026 revenue outlook from decline to mid-single-digit growth.
| Quarter | Q2 FY26 |
|---|---|
| Call date | 2026-07-29 |
| Length | 69 minutes |
| EPS | $3.60 |
| EPS consensus | $3.04 |
| Revenue | $2.7B |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q1 FY26 · Q4 FY25 · Q3 FY25 · Q2 FY25 · Q1 FY25 · Q4 FY24
Read the full Q2 FY26 earnings call transcript
All BIIB earnings · Back to BIIB overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.